memo-inOncology – SPECIAL ISSUE

Find out the latest news from international oncology congresses and stay at the forefront of clinical innovation and advances in lung cancer research. Each SPECIAL ISSUE – CONGRESS REPORT features informative summaries of key topics from lung cancer to come out of a major international oncology congress.

The memo inOncology Medical education series: keeping oncologists at the forefront of lung cancer research. memo – inOncology Special Issue Preceptorship reports summarise the latest in lung cancer research and treatments to come out of our sponsored Preceptorship meeting series. The Fundamentals of Designing Clinical Trials series arms oncologists with the information they need to plan and conduct an oncology trial.

Congress reports

REGISTER

Get a notification for every published memo – inOncology SPECIAL ISSUE. Register below.


    LATEST NEWS

    ASH 2020 English Cover

    memo – inOncology SPECIAL ISSUE

    Congress Report virtual ASH 2020

    The memoinOncology ASH 2020 congress report summarizes highlights from the latest clinical trials in B-Cell malignancies, with a focus on BTK inhibition and PD-1 inhibition. Indications include chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström’s macroglobulinemia, marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL), as well as other B-cell malignancies.

    ESMO 2020 Lung Cancer English

    memo – inOncology SPECIAL ISSUE

    Congress Report virtual ESMO 2020 Lung Cancer

    The memoinOncology ESMO 2020 congress report summarizes highlights from the latest clinical trials in lung cancer, with a focus on PD-1 inhibition and EGFR-targeted options. Optimal therapies in early-stage lung cancer, determinants of treatment success in small cell lung cancer and interactions between radiotherapy and the immune system are among other topics reviewed.

    Now available!

    VIEW ALL OUR REPORTS

    EXPERT VIDEOS

    All videointerviews from virtual ASH 2020

    Steven P. Treon explains about innovative approaches in the treatment of Waldenström’s macroglobulinemia, future aspects and the successful use of BTK inhibition within niche groups of patients with WM, and potential benefits of BTK inhibitors regarding COVID-19 complications.

    Jorge Castillo relates to recent developments with respect to follicular lymphoma, multiple myeloma and Waldenström’s macroglobulinemia, current insights into CAR-T cell therapy in the setting of multiple myeloma, and the future of anti-CD38 antibody treatment in patients with Waldenström’s macroglobulinemia.

    Alessandra Tedeschi summarizes the results from the MAGNOLIA and iNNOVATE trials, relates to recent advances in the management of marginal zone lymphoma and discusses the effect of the introduction of BTK inhibition on the prognosis of patients with Waldenström’s macroglobulinemia.

    Stephen Opat discusses the requirements for treatment-free long-term remission in the setting of CLL and talks about the future of BTK inhibitors and promising combinations in B-cell malignancies in general, as well as the strengths and limitations of immune checkpoint inhibitors.

    All videointerviews from ESMO Lung Cancer 2020

    Tony Mok summarizes insights into the immunotherapeutic management of patients with advanced lung cancer who receive PD-1 inhibitors and relates to aspects of biomarker-based treatment selection, patient prognosis, and new agents that might change the treatment landscape.

    Byoung Chul Cho explains about the rationale and outcomes for combined targeted treatment of lung cancer patients with an emphasis on EGFR-mutant disease and describes findings obtained for a first-in-class agent targeting the KRASG212C mutation.

    Maarten Lambrecht highlights aspects of radiobiology regarding interactions between radiotherapy and the immune system, non-invasive imaging biomarkers and trial results presented at ESMO 2020 that bear importance from a radiation oncologist’s point of view.

    Paul Baas discusses the prognosis and treatment of patients with malignant mesothelioma, relating to combined modality treatment with immune checkpoint inhibitors plus chemotherapy and talks about other immunotherapeutic approaches beyond checkpoint inhibition.

    VIEW MEDICAL EDUCATION